151 related articles for article (PubMed ID: 28099210)
41. Pazopanib is an active treatment in desmoid tumour/aggressive fibromatosis.
Martin-Liberal J; Benson C; McCarty H; Thway K; Messiou C; Judson I
Clin Sarcoma Res; 2013 Nov; 3(1):13. PubMed ID: 24279994
[TBL] [Abstract][Full Text] [Related]
42. An open-label extension study to evaluate safety and efficacy of pazopanib in patients with advanced renal cell carcinoma.
Sternberg CN; Davis ID; Deen KC; Sigal E; Hawkins RE
Oncology; 2014; 87(6):342-50. PubMed ID: 25227656
[TBL] [Abstract][Full Text] [Related]
43. Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial.
Necchi A; Mariani L; Zaffaroni N; Schwartz LH; Giannatempo P; Crippa F; Morosi C; Lanocita R; Sava T; Ortega C; Messina C; Sacco C; Pennati M; Daidone MG; Nicolai N; De Braud F; Gianni AM; Salvioni R
Lancet Oncol; 2012 Aug; 13(8):810-6. PubMed ID: 22819172
[TBL] [Abstract][Full Text] [Related]
44. Efficacy of pazopanib monotherapy in patients who had been heavily pretreated for metastatic soft tissue sarcoma: a retrospective case series.
Yoo KH; Kim HS; Lee SJ; Park SH; Kim SJ; Kim SH; La Choi Y; Shin KH; Cho YJ; Lee J; Rha SY
BMC Cancer; 2015 Mar; 15():154. PubMed ID: 25885855
[TBL] [Abstract][Full Text] [Related]
45. Phase I combination of pazopanib and everolimus in PIK3CA mutation positive/PTEN loss patients with advanced solid tumors refractory to standard therapy.
Rodrigues HV; Ke D; Lim J; Stephen B; Bellido J; Janku F; Zinner R; Tsimberidou A; Hong D; Piha-Paul S; Fu S; Naing A; Subbiah V; Karp D; Falchook G; Kurzrock R; Wheler J
Invest New Drugs; 2015 Jun; 33(3):700-9. PubMed ID: 25902899
[TBL] [Abstract][Full Text] [Related]
46. Incorporation of pazopanib in maintenance therapy of ovarian cancer.
du Bois A; Floquet A; Kim JW; Rau J; del Campo JM; Friedlander M; Pignata S; Fujiwara K; Vergote I; Colombo N; Mirza MR; Monk BJ; Kimmig R; Ray-Coquard I; Zang R; Diaz-Padilla I; Baumann KH; Mouret-Reynier MA; Kim JH; Kurzeder C; Lesoin A; Vasey P; Marth C; Canzler U; Scambia G; Shimada M; Calvert P; Pujade-Lauraine E; Kim BG; Herzog TJ; Mitrica I; Schade-Brittinger C; Wang Q; Crescenzo R; Harter P
J Clin Oncol; 2014 Oct; 32(30):3374-82. PubMed ID: 25225436
[TBL] [Abstract][Full Text] [Related]
47. Pazopanib for the treatment of breast cancer.
Amiri-Kordestani L; Tan AR; Swain SM
Expert Opin Investig Drugs; 2012 Feb; 21(2):217-25. PubMed ID: 22233389
[TBL] [Abstract][Full Text] [Related]
48. Pazopanib. Kidney cancer: many risks, but is there a benefit for patients?
Prescrire Int; 2011 Mar; 20(114):64-6. PubMed ID: 21648224
[TBL] [Abstract][Full Text] [Related]
49. Pazopanib a tyrosine kinase inhibitor with strong anti-angiogenetic activity: a new treatment for metastatic soft tissue sarcoma.
Ranieri G; Mammì M; Donato Di Paola E; Russo E; Gallelli L; Citraro R; Gadaleta CD; Marech I; Ammendola M; De Sarro G
Crit Rev Oncol Hematol; 2014 Feb; 89(2):322-9. PubMed ID: 24041629
[TBL] [Abstract][Full Text] [Related]
50. Pazopanib outscores sunitinib on tolerability.
Cancer Discov; 2014 Jan; 4(1):OF8. PubMed ID: 24402960
[TBL] [Abstract][Full Text] [Related]
51. Efficacy of imatinib in aggressive fibromatosis: Results of a phase II multicenter Sarcoma Alliance for Research through Collaboration (SARC) trial.
Chugh R; Wathen JK; Patel SR; Maki RG; Meyers PA; Schuetze SM; Priebat DA; Thomas DG; Jacobson JA; Samuels BL; Benjamin RS; Baker LH;
Clin Cancer Res; 2010 Oct; 16(19):4884-91. PubMed ID: 20724445
[TBL] [Abstract][Full Text] [Related]
52. Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer.
Monk BJ; Mas Lopez L; Zarba JJ; Oaknin A; Tarpin C; Termrungruanglert W; Alber JA; Ding J; Stutts MW; Pandite LN
J Clin Oncol; 2010 Aug; 28(22):3562-9. PubMed ID: 20606083
[TBL] [Abstract][Full Text] [Related]
53. A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update.
Sternberg CN; Hawkins RE; Wagstaff J; Salman P; Mardiak J; Barrios CH; Zarba JJ; Gladkov OA; Lee E; Szczylik C; McCann L; Rubin SD; Chen M; Davis ID
Eur J Cancer; 2013 Apr; 49(6):1287-96. PubMed ID: 23321547
[TBL] [Abstract][Full Text] [Related]
54. A Case of Uterine Leiomyosarcoma with Long-Term Disease Control by Pazopanib.
Nagamata S; Ebina Y; Yamano Y; Miyamoto T; Nishijima M; Yamada H
Kobe J Med Sci; 2016 Jul; 62(2):E45-8. PubMed ID: 27578036
[TBL] [Abstract][Full Text] [Related]
55. Medical treatment of mammary desmoid-type fibromatosis: which benefit?
Scheer L; Lodi M; Molière S; Kurtz JE; Mathelin C
World J Surg Oncol; 2017 Apr; 15(1):86. PubMed ID: 28420393
[TBL] [Abstract][Full Text] [Related]
56. Pazopanib in the treatment of soft tissue sarcoma.
Schöffski P
Expert Rev Anticancer Ther; 2012 Jun; 12(6):711-23. PubMed ID: 22716487
[TBL] [Abstract][Full Text] [Related]
57. Pazopanib versus sunitinib for the treatment of metastatic renal cell carcinoma patients with poor-risk features.
Kim JH; Park I; Lee JL
Cancer Chemother Pharmacol; 2016 Aug; 78(2):325-32. PubMed ID: 27324136
[TBL] [Abstract][Full Text] [Related]
58. Real-World Outcome and Prognostic Factors of Pazopanib in Advanced Soft Tissue Sarcoma.
Alshamsan B; Badran A; Alshibany A; Maraiki F; Elshenawy MA; Elhassan T; Atallah JP
Cancer Manag Res; 2021; 13():6755-6766. PubMed ID: 34512015
[TBL] [Abstract][Full Text] [Related]
59. Health-related quality-of-life results from PALETTE: A randomized, double-blind, phase 3 trial of pazopanib versus placebo in patients with soft tissue sarcoma whose disease has progressed during or after prior chemotherapy-a European Organization for research and treatment of cancer soft tissue and bone sarcoma group global network study (EORTC 62072).
Coens C; van der Graaf WT; Blay JY; Chawla SP; Judson I; Sanfilippo R; Manson SC; Hodge RA; Marreaud S; Prins JB; Lugowska I; Litière S; Bottomley A
Cancer; 2015 Sep; 121(17):2933-41. PubMed ID: 26033286
[TBL] [Abstract][Full Text] [Related]
60. Pazopanib, a potent orally administered small-molecule multitargeted tyrosine kinase inhibitor for renal cell carcinoma.
Sonpavde G; Hutson TE; Sternberg CN
Expert Opin Investig Drugs; 2008 Feb; 17(2):253-61. PubMed ID: 18230058
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
